Dihydroquercetin as a potential immunonutrient in the complex therapy of COVID-19

Institute of Geochemistry n.a. A.P. Vinogradov, Irkutsk, Russia

About:
The biological activity of DHQ is aimed at restoring the normal functioning of all major target organs SARS-CoV-2 such as lungs, heart, liver and others. In addition, DHQ is an anticoagulant and a powerful antioxidant, which helps to normalize blood hematological parameters. Positive results from clinical trials conducted earlier in the treatment of acute pneumonia suggest that DHQ may also be used to treat pneumonia caused by the novel coronavirus infection, COVID-19. The ability of DHQ to excrete toxic free iron, which is formed as a result of the degradation of hemoglobin under the influenceSARSCoV-2, can significantly reduce tissue degradation and reduce the burden on the liver against the background of COVID-19. All of the above allows us to consider DHQ as a potential immunonutrient in complex therapy.SARS-CoV-2 , significantly reduce tissue degradation and reduce the burden on the liver against the background of COVID-19.
Article Language: RUS
Date of publish: 22 October 2021

Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease.
Research Hanover Medical School, Germany

About:
Attention to the possible effective use of Dihydroquercetin (also known as Taxifolin) in the prevention and relief of COVID-19 has been significantly confirmed by scientists from Germany.
The study was conducted in several stages and was based on previously appeared assumptions that a specific agent of the immune system called prostaglandin PGE2 can change (inhibit and modify inadequately) the immune response in people at risk of infection or currently suffering from COVID-19 coronavirus.
Dihydroquercetin has shown a significant effect on reducing the negative effect of PGE2 on the formation of the immune response. According to scientists, Dihydroquercetin can be considered as a serious alternative to nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment and prevention of viral infections, and in particular, SARS COVID-19.
Article Language: ENG
Date of publish: 04 August 2021

“Computational guided identifcation of a citrus favonoid as potential inhibitor of SARS‑CoV‑2 main protease”

About:
Computer simulations made by Indian scientists show the advantage of DHQ in blocking the attack on the human body of the COVID 19 virus and its possible mutations. The in silico study, conducted on model schemes of interaction between the COVID19 virus and the human immune system, shows the advantage of DHQ in the formation of strong compounds with the active centers of the COVID19 virus, which can effectively prevent infection of the body with this virus. The advantage of Dihydroquercetin is demonstrated in comparison with several pre-selected natural substances that have similar antiviral potential to DHQ. Among these substances is quercetin, which is included in the treatment protocols of COVID19. The study confirms the assumption made earlier in the scientific and medical community of the Russian Federation and the world about the preference of DHQ to quercetin in the treatment and maintenance schemes for COVID19. An important result of the study is the assumption about the possible potential of DHQ to be an active antiviral agent in mutations
Article Language: ENG
Date of publish: 25 November 2020

Dihydroquercetin is an assistant in the fight against coronavirus. Research University of Basel, Switzerland

About:
The study identified 11 compounds that can have a positive effect on patients with COVID-19, one of which is dihydroquercetin
Article Language: ENG
Date of publish: 2020

“Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19) and its complications”

About: 
The study looks at the prospects for the use of several components, one of which is dihydroquercetin, for the treatment and recovery from COVID-19.
Article Language: RUS

“Arabinogalactan extract improves antibody response to pneumonia vaccine”

About:
The study found that taking arabinogalactan is able to increase the antibody response to the level of 23-valent vaccines against pneumococcal infection (PNEUMO 23).
Date of publish: ENG

Robios translation of the COVID-19 Intensive Care Protocol developed by Paul Marik, M.D., Head of Pulmonology and Critical Care Unit, East Virginia School of Medicine

Article Language: RUS

“Does Arabinogalactan Improve Immune Functioning? Clinical Trials Review”

About: 
Recent human studies have shown that arabinogalactan can increase the body’s resistance to colds and has an immunostimulating effect.
Article Language: ENG

“Influence of Arabinogalactan on the incidence of respiratory diseases”

About:
Research on the ability of arabinogalactan to prevent the development of colds and on the possibility of using it as a prophylactic agent.
Article Language: ENG

“Quercetin: Antiviral Significance and Possible COVID-19 Integrative Considerations”

About:
This review summarizes the antiviral significance of quercetin and proposes a possible strategy for the effective utilization of natural polyphenols in our daily diet for the prevention of viral infection.
Article Language: ENG
Date of publish: 2020

“Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study”

About: 
QP is a safe agent and in combination with standard care, when used in early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease.
Article Language: ENG
Date of publish:  2021

“Perspectives on plant flavonoid quercetinbased drugs for novel SARS-CoV-2”

About:
The antiviral properties of flavonoid and the molecular mechanisms involved are reviewed. Further, proof for this concept is given by docking of key proteins from SARS-CoV-2 with quercetin.

Article Language: ENG (Тут перевод)
Date of publish: 2021

“Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study”

About:
Quercetin may be a novel therapeutic agent for COVID-19-induced AKI. Inhibition of inflammatory, cell apoptosis-related signaling pathways may be the critical mechanisms by which Quercetin protects kidney from SARS-CoV-2 injury.
Article Language: ENG
Date of publish: 04 Ноября 2020

“Treatment of COVID-19 Patients with Quercetin: A Prospective, Single – Centre, Randomized, Controlled Trial”

About: 
While there was no difference between the groups in terms of event frequency, QCB group had more advanced pulmonary findings. QCB supplement is shown to have a positive effect on laboratory recovery. Conclusion We suggest that suboptimal bioavailability of QCB may explain this. So, we conclude that if a stable blood level can be achieved for QCB, it may make a difference in the treatment of COVID-19.
Article Language: ENG
Date of publish: 2021

“Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV”

About:
This study is the first to reveal quercetin as a pharmacological drug for COVID-19 and DENGUE co-infection. COVID-19 and DENGUE co-infection remain a potential threat to the world’s public health system.
Article Language: ENG
Date of publish: 2021

“Anti-inflammatory potential of Quercetin in COVID-19 treatment”

About: 
Quercetin, as an anti-inflammatory, antioxidant, analgesic and inflammatory compound, is probably a potential treatment for severe inflammation and one of the main life-threatening conditions in patients with COVID-19.
Article Language: ENG
Date of publish: 2021